- 10:04 AM India prepares for first full FATF review to begin...
- 10:04 AM Reliance Industries up on news of cum bonus trade
- 10:00 AM Keep Rs 275 stoploss in GE Shipping: Sukhani
- 09:55 AM Sensex volatile ahead of expiry tomorrow; ICICI Bk...
- 09:53 AM Buy Andhra Bank, says Sudarshan Sukhani
- 09:51 AM Market may remain choppy: Astroprofit
- 09:48 AM Key support for Nifty at 5050-5060: Reliance Money
- 09:45 AM Markets likely to remain range-bound: Khandwala Se...
- 09:43 AM Accumulate shipping stocks on dips: astrostocktips
- 09:39 AM Tata tea looks positive: Astromoneyguru
Zydus Cadila has received an approval from the USFDA for Hydroxychloroquine Sulfate Tablets in the strength of 200 mg. The drug falls in the DMARD (Disease Modifying Anti-Rheumatic Drug) segment and is used in the management of rheumatoid arthritis. The sales of Hydroxychloroquine Sulfate Tablets in the US market in 2006 as per NDC Health was estimated at USD $ 30 mn.
The company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group has 27 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 65 ANDAs and 55 DMFs.
Sourced From: Pressman India
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Expert sector picks to power your portfolio ahead
- Mitesh Thacker's top 5 picks for trade today
- Will ITC dream run continue beyond FY10?
- Moody's maintains negative view on India's credit condition
- Bollywood actress Shilpa Shetty marries Raj Kundra
- Den Networks closes 16% lower on first day
- Air India saves Rs 400cr through restructuring
- Worst over for India auto companies: Anand Mahindra
- Mahindra may increase car prices due to rising input costs
Source: Business Line
- Renault to continue with M&M for Logan, says Ghosn
Source: Business Line
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line
